Search results for "g factor"

showing 10 items of 514 documents

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Platelet-activating factor type activity in plasma from patients with septicemia and other diseases

1991

The purpose of the present study was to determine whether increased levels of platelet-activating factor (PAF) type activity can be detected in plasma from patients with septicemia and other diseases. A level of PAF below 0.5 ng/mL of plasma was considered normal. We found that plasma from a patient with adverse anaphylactoidic reaction to intravenous analgetics contained 2.1 ng PAF/mL. In seven patients with septicemia, including urosepsis, endocarditis and peritonitis, and with positive blood culture, increased plasma PAF levels (1-20 ng PAF/mL) were observed. Other patients with clinical indications of septicemia had negative blood cultures and/or increased levels of C-reactive protein (…

AdultBlood PlateletsMalemedicine.medical_specialtyPlatelet AggregationClinical chemistryPeritonitisBacteremiaBiochemistrySepsischemistry.chemical_compoundReference ValuesInternal medicinemedicineAnimalsHumansPlateletPlatelet Activating FactorPlatelet-activating factorPlatelet CountSeptic shockbusiness.industryOrganic ChemistryAntagonistAzepinesCell BiologyMiddle AgedTriazolesrespiratory systemmedicine.diseaseThrombocytopenic purpuraC-Reactive ProteinEndocrinologyPurpura ThrombocytopenicchemistryImmunologyFemalelipids (amino acids peptides and proteins)RabbitsbusinessLipids
researchProduct

Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

1989

Abstract The effect of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematologic parameters was evaluated in a phase I clinical study in 18 patients with advanced malignancy. G-CSF was administered once daily as a 30-minute infusion for 14 days; three patients each were treated at increasing dose levels of 1, 3, 10, 30, and 60 micrograms kg-1 day-1. A transient decrease in neutrophil and monocyte counts was observed immediately after the G-CSF infusion, followed by a dose-dependent increase of up to 15-fold. G-CSF-induced neutrophils exhibited an increased O2- radical production, and serum levels of enzymes related to granulocyte turnover, including lysozyme and elastas…

AdultBlood Plateletsmedicine.medical_specialtySide effectImmunologyAntineoplastic AgentsPlatelet Membrane GlycoproteinsGranulocyteMalignancyBiochemistryLeukocyte CountColony-Stimulating FactorsSuperoxidesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPlateletBone painAgedbusiness.industryPlatelet CountMonocyteElastaseReceptors Interleukin-2Cell BiologyHematologyMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorHematopoiesisEndocrinologymedicine.anatomical_structureImmunologyDrug Evaluationmedicine.symptombusinessBlood
researchProduct

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy

2020

OBJECTIVE: Adult drug-resistant epilepsy (DRE) is associated with significant morbidity. Infiltration of immune cells is observed in DRE epileptic foci; however, the relation between DRE and the peripheral immune cell compartment remains only partially understood. We aimed to investigate differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well-controlled epilepsy (WCE). METHODS: Peripheral blood mononuclear cells and serum from >120 age- and sex-matched adults suffering from focal onset epilepsy and controls were analyzed by multipanel flow cytometry, multiplex i…

AdultCD4-Positive T-LymphocytesMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_treatmenturologic and male genital diseasesPeripheral blood mononuclear cellProinflammatory cytokineInterferon-gammaYoung Adult03 medical and health sciencesEpilepsyTh2 Cells0302 clinical medicineImmune systemNeurofilament ProteinsmedicineHumansImmunoassayInflammationEpilepsyTumor Necrosis Factor-alphabusiness.industryInterleukinsInterleukin-17NeurotoxicityGranulocyte-Macrophage Colony-Stimulating FactorInterleukinMiddle AgedFlow Cytometrymedicine.diseaseSingle Molecule ImagingCD4 Lymphocyte CountInterleukin-10030104 developmental biologyCytokineNeurologyCase-Control StudiesImmunologyCytokinesTh17 CellsFemaleTumor necrosis factor alphaInterleukin-4Neurology (clinical)business030217 neurology & neurosurgery
researchProduct

Sequential analysis of CD34+ and CD34− cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plu…

2001

Administration of stem cell factor (SCF) has been proven to enhance cytokine-induced mobilization of CD34+ hematopoietic progenitor cells (HPC) into the peripheral blood (PB). The aim of the present study was to explore in a homogeneous group of 22 uniformly treated breast cancer patients: (1) the kinetics of mobilization into PB of both CD34+ and CD34- cell subsets, including dendritic cells, in sequential samples obtained from day +7 up to day +12 after mobilization; and (2) the composition of the CD34+ and CD34- cell subsets present in the two leukapheresis products obtained for each patient. The following CD34+ and CD34- subsets were analyzed: early CD34+ HPC, erythroid-, myeloid- and B…

AdultCancer ResearchAdolescentCD14CD34Antigens CD34Breast NeoplasmsStem cell factorBiologyImmunophenotypingGranulocyte Colony-Stimulating FactorHumansLeukapheresisAntigen-presenting cellCyclophosphamideHematopoietic Stem Cell MobilizationAgedStem Cell FactorHematologyDendritic cellLeukapheresisMiddle AgedMolecular biologyHematopoietic Stem Cell MobilizationRecombinant ProteinsGranulocyte colony-stimulating factorOncologyImmunologyFemaleLeukemia
researchProduct

Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer pr…

2002

The objective of our study was to determine the effect of adding r-metHuSCF to Filgrastim and cyclophosphamide for mobilization of peripheral blood progenitor cells (PBPC), on collection of CD34(+) cells and engraftment after autologous stem cell transplant. Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. Two PBPC collections were performed on consecutive days starting the day the WBC count was above 7.5 x 10(3)/microl. Collection was performed between days +9 and +12 and the median number of CD34(+) cells collected was 9.9 x 10(6)/kg (1.1-53.1) and 6.6 x 10(6)/kg (1…

AdultCancer Researchmedicine.medical_specialtyFilgrastimPlatelet EngraftmentCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsFilgrastimTransplantation Autologouschemistry.chemical_compoundInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansNeoplasm MetastasisProgenitor cellCyclophosphamideAgedNeoplasm StagingStem Cell FactorChemotherapybusiness.industryHematologyMiddle AgedHematopoietic Stem CellsHematopoietic Stem Cell MobilizationRecombinant ProteinsNitrogen mustardGranulocyte colony-stimulating factorTransplantationTreatment OutcomeEndocrinologyOncologychemistryLymphatic MetastasisFemalebusinessStem Cell Transplantationmedicine.drugLeukemia
researchProduct

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

2010

The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) were given 240 μg/kg plerixafor SC 9-11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 10(6) CD34(+) cells/μL. The median cell yield was 3.35 × 10(6) CD34+ cells/kg (0-29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 …

AdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesAdolescentStem cell mobilizationmedicine.medical_treatmentCyclamsPoor mobilizersGermanYoung AdultHeterocyclic CompoundsGermanyGranulocyte Colony-Stimulating FactormedicineHumansIntensive care medicineChildAgedTransplantationChemotherapybusiness.industryPlerixaforLymphoma Non-HodgkinHematopoietic Stem Cell TransplantationCompassionate UseHematologyMiddle AgedCombined Modality TherapyHodgkin Diseasehumanitieslanguage.human_languageHematopoietic Stem Cell MobilizationTreatment OutcomeChild PreschoollanguageBlood Component RemovalFemalebusinessMultiple Myelomamedicine.drugBone marrow transplantation
researchProduct

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in pati…

1993

After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte - colony stimulating factor (G- CSF) 5 μg/Kg/day in order to prevent severe neutropenia and its related morbidity. The incidence of neutropenia (absolute neutrophil count <1, 000/mm3) was significantly reduced in patients receiving G-CSF than in controls (18% versus 42%; P <0.05). The duration of neutropenia was also shortened by the administration of G-CSF (4.8 versus 8.2 days; P <0.05). Therapy with G-CSF has also a positive impact on the dose-intensity of employed regimens. Patients treated with G-CSF showed…

AdultMale0301 basic medicineMicrobiology (medical)medicine.medical_specialtyNeutropeniaTime FactorsFeverInjections Subcutaneousmedicine.medical_treatment030106 microbiologyAntineoplastic AgentsNeutropeniaGranulocytePlaceboGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)Prospective StudiesNeoplasm MetastasisAgedPharmacologyChemotherapybusiness.industryIncidenceIncidence (epidemiology)CarcinomaMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorSurgeryInfectious DiseasesGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncology030220 oncology & carcinogenesisAbsolute neutrophil countFemalebusinessmedicine.drug
researchProduct

A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease

2017

IF 5.340; International audience; The main identified function of BCL2 protein is to prevent cell death by apoptosis. Mice knock-out for Bcl2 demonstrate growth retardation, severe polycystic kidney disease (PKD), gray hair and lymphopenia, and die prematurely after birth. Here, we report a 40-year-old male referred to for abdominal and thoracic aortic dissection with associated aortic root aneurysm, PKD, lymphocytopenia with a history of T cell lymphoblastic lymphoma, white hair since the age of 20, and learning difficulties. PKD, which was also detected in the father and sister, was related to an inherited PKD1 mutation. The combination of PKD with gray hair and lymphocytopenia was also r…

AdultMale0301 basic medicineTRPP Cation Channelsphenotypebcl2 geneBiologymicro rnaMice03 medical and health sciencesdown-regulationsymptom aggravating factorshemic and lymphatic diseasest-lymphocyteGene expressionGeneticsmedicinePolycystic kidney diseaseAnimalsHumansGenetic Predisposition to Disease[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsgenesMolecular BiologyGeneGenetics (clinical)Exome sequencingMice KnockoutPKD1apoptosisExonsGeneral MedicinePolycystic Kidney Autosomal Dominantmedicine.diseasePhenotypePedigreeUp-Regulation3. Good healthMicroRNAs030104 developmental biologyMRNA SequencingProto-Oncogene Proteins c-bcl-2[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsImmunologyCancer researchLymphocytopeniapolycystic kidney diseasesbcl-2 proteinHuman Molecular Genetics
researchProduct

Social factors related to the clinical severity of influenza cases in Spain during the A (H1N1) 2009 virus pandemic

2013

Abstract Background During the 2009 influenza pandemic, a change in the type of patients most often affected by influenza was observed. The objective of this study was to assess the role of individual and social determinants in hospitalizations due to influenza A (H1N1) 2009 infection. Methods We studied hospitalized patients (cases) and outpatients (controls) with confirmed influenza A (H1N1) 2009 infection. A standardized questionnaire was used to collect data. Variables that might be related to the hospitalization of influenza cases were compared by estimation of the odds ratio (OR) and 95% confidence intervals (CI) and the variables entered into binomial logistic regression models. Resu…

AdultMaleAdolescentComorbidityInfluenza A Virus H1N1 SubtypeOccupational ExposureInfluenza HumanHumansMass ScreeningChildPandemicsPandemiclcsh:Public aspects of medicineInfant NewbornPublic Health Environmental and Occupational HealthInfantvirus diseaseslcsh:RA1-1270Confounding Factors EpidemiologicHealth Status DisparitiesHospitalizationInfluenza A (H1N1) 2009Social ClassSocial factorsSpainCase-Control StudiesChild PreschoolFemaleResearch ArticleBMC Public Health
researchProduct